Natixis’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-1,339,811
| Closed | -$246M | – | 1306 |
|
|
2021
Q2 | $246M | Sell |
1,339,811
-316,689
| -19% | -$54.4M | 1.08% | 13 |
|
|
2021
Q1 | $253M | Buy |
1,656,500
+1,220,007
| +280% | +$189M | 0.83% | 16 |
|
|
2020
Q4 | $68.2M | Buy |
+436,493
| New | +$56.1M | 0.25% | 89 |
|
|
2020
Q3 | – | Sell |
-57,196
| Closed | -$6.42M | – | 914 |
|
|
2020
Q2 | $6.42M | Buy |
57,196
+50,749
| +787% | +$5.39M | 0.05% | 249 |
|
|
2020
Q1 | $579K | Sell |
6,447
-45,701
| -88% | -$4.49M | ﹤0.01% | 554 |
|
|
2019
Q4 | $5.6M | Buy |
+52,148
| New | +$5.58M | 0.03% | 389 |
|
|
2018
Q3 | – | Sell |
-44,310
| Closed | -$5.5M | – | 1018 |
|
|
2018
Q2 | $5.5M | Buy |
44,310
+26,546
| +149% | +$3.1M | 0.03% | 367 |
|
|
2018
Q1 | $1.98M | Sell |
17,764
-482,267
| -96% | -$57.6M | 0.01% | 510 |
|
|
2017
Q4 | $59.8M | Buy |
500,031
+425,764
| +573% | +$51.9M | 0.46% | 56 |
|
|
2017
Q3 | $10.4M | Buy |
+74,267
| New | +$10.1M | 0.1% | 189 |
|
|
2017
Q2 | – | Sell |
-224,613
| Closed | -$27.2M | – | 1032 |
|
|
2017
Q1 | $27.2M | Buy |
+224,613
| New | +$29M | 0.34% | 80 |
|
|
2014
Q3 | – | Sell |
-39,168
| Closed | -$6.12M | – | 496 |
|
|
2014
Q2 | $6.12M | Sell |
39,168
-18,200
| -32% | -$2.87M | 0.07% | 166 |
|
|
2014
Q1 | $8.73M | Buy |
57,368
+5,075
| +10% | +$807K | 0.11% | 139 |
|
|
2013
Q4 | $6.96M | Buy |
+52,293
| New | +$6.28M | 0.06% | 201 |
|
|
2013
Q3 | – | Sell |
-8,300
| Closed | -$766K | – | 574 |
|
|
2013
Q2 | $766K | Buy |
+8,300
| New | +$800K | 0.01% | 301 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM